ACET
Adicet BioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ACET Profile
Adicet Bio, Inc.
A company that developing novel therapeutics for the treatment of aging-related diseases
131 Dartmouth Street, 3rd Floor, Boston, MA 02116
--
Adicet Bio, Inc., was incorporated under the laws of the State of Delaware on July 5, 2016. The company is a clinical-stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies for cancer. They are advancing a series of "off-the-shelf" gamma delta T cells designed with chimeric antigen receptors (CAR) and T cell receptor like antibodies (TCRL) to enhance tumor selective targeting, promote innate and adaptive anti-tumor immune response, and improve the persistence of long-lasting activity in patients. Their method of activating, designing and manufacturing allogeneic gamma delta T cell product candidates from peripheral blood cells of unrelated donors enables them to generate new product candidates in a rapid and cost-effective manner.
